Alkermes announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2, NT2, and idiopathic hypersomnia, IH, at the European Sleep Research Society’s, ESRS, 27th Congress, Sleep Europe 2024, taking place Sept. 24-27, 2024 in Seville, Spain. ALKS 2680 is the company’s novel, investigational, oral, selective orexin 2 receptor, OX2R, agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. In an oral presentation and corresponding poster presentation, the company will share data from the cohort of patients with NT2 from the phase 1b, proof-of-concept study evaluating single-dose, oral administration of ALKS 2680. Additionally, the company will present a poster with data from the cohort of patients with IH from the same study. As previously announced, ALKS 2680 was generally well tolerated with improved wakefulness compared to placebo in both cohorts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Mizuho says hard to tell yet how Centessa and Alkermes stack up in narcolepsy
- Alkermes initiates Vibrance-2 Phase 2 study evaluating ALKS 2680
- Fulcrum appoints Isabel Kalofonos as CCO
- Alkermes price target raised to $38 from $37 at Baird
- Alkermes price target raised to $37 from $35 at H.C. Wainwright